文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

靶向治疗时代全脑放疗用于NSCLC软脑膜转移的回顾性研究

Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.
PubMed 文献 · Radiat Oncol · 2020-07-31

该回顾性研究分析80例细胞学或影像学确诊的NSCLC软脑膜转移患者,发现EGFR突变者中位OS为12.6个月,野生型仅4.1个月;WBRT在EGFR突变者中未显示生存获益(P=0.490),但在野生型患者中显著延长生存(8.0 vs 2.1个月,P=0.002),提示应按分子分型选择WBRT。

要点

  • EGFR突变软脑膜转移患者mOS为12.6个月,野生型仅4.1个月(P<0.001)。
  • WBRT未改善EGFR突变患者生存(P=0.490),但显著延长野生型患者mOS(8.0 vs 2.1个月,P=0.002)。
  • 多因素分析显示WBRT(P=0.025)和年轻年龄(P=0.048)是野生型患者独立预后因素。

核心结论

  • WBRT对EGFR野生型NSCLC软脑膜转移患者有明确生存优势,推荐按分子生物学分层选择WBRT。

研究设计与样本

  • 回顾性分析2014年12月至2019年3月80例细胞学和/或影像学确诊软脑膜转移的NSCLC患者。

主要发现

  • 软脑膜转移诊断后中位OS为8.0个月(95%CI: 4.4–11.6),1年OS为39.4%。
  • EGFR突变患者mOS为12.6个月(95%CI: 3.0–22.2),野生型为4.1个月(95%CI: 2.8–5.4),P<0.001。
  • 年龄<53.5岁患者OS优于≥53.5岁者(12.6 vs 6.1个月,P=0.041)。
  • EGFR突变患者接受WBRT未见生存获益(P=0.490);野生型患者WBRT组mOS为8.0个月,非WBRT组为2.1个月(P=0.002)。
  • 多因素分析显示WBRT(P=0.025)和年轻年龄(P=0.048)是野生型患者独立预后因素。

临床怎么用

  • 对EGFR野生型NSCLC软脑膜转移患者,可考虑WBRT以延长生存。
  • 对EGFR突变患者,WBRT未见生存获益,决策时应结合靶向治疗并权衡神经认知毒性。
  • 软脑膜转移患者行WBRT前建议进行EGFR分子分型以指导分层治疗。

局限性

  • 回顾性研究,样本量80例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Leptomeningeal metastasis (LM) is a rare but detrimental complication in patients with non-small cell lung cancer (NSCLC). Although whole brain radiotherapy (WBRT) is used to eliminating cancer cells or microscopic foci, it is becoming less favorable due to the concerns over neurocognitive toxicity. This study aimed to re-evaluate the role of WBRT in the setting of modern targeted therapy. MATERIALS AND METHODS: From December 2014 to March 2019, 80 NSCLC patients with cytologically and/or radiologically proven LM diagnosis were retrospectively analyzed. RESULTS: The median OS (mOS) after diagnosis of LM was 8.0 (95%CI: 4.4 to 11.6) months, and the one-year OS was 39.4%. The mOS for EGFR-mutated LM patients was 12.6 (3.0 to 22.2) months versus only 4.1 (2.8 to 5.4) for patients with wild-type EGFR (P < 0.001). Younger patients (< 53.5 yrs.) appeared to have a better OS than older patients (≥53.5 yrs.) (12.6 vs. 6.1, P = 0.041). No survival benefits were found in EGFR-mutated patients who received WBRT (P = 0.490). In contrast, mOS was significantly prolonged in wild-type EGFR patients with WBRT versus non-WBRT (mOS: 8.0 vs. 2.1, P = 0.002). Multivariate analysis indicated that WBRT (P = 0.025) and younger age (P = 0.048) were independent prognostic factors that predicted prolonged survival for wild-type EGFR LM patients from NSCLC. CONCLUSION: Our study demonstrated that WBRT has clear survival advantages for patients with wild-type EGFR, and molecular biological stratification of LM patients for WBRT is highly recommended.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhen J, Wen L, Lai M, et al. Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiat Oncol. 2020. PMID: 32736566. doi:10.1186/s13014-020-01627-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。